US health care reform team emerges after Daschle setback, biogenerics promised

9 March 2009

The new federal administration of President Barack Obama is putting  together the team it hopes will deliver a major health care reform  package, following the setback of former US Senator Tom Daschle's failed  nomination as Secretary of Health and Human Services (Marketletter  February 9) over tax evasion claims. The new choice of HHS Secretary is  Governor Kathleen Sebelius (Democrat, Kansas), who was widely rumored to  be the then presidential candidate's most favored female choice for  running mate shortly before the Democratic convention last year.

The White House Office for Health Reform, in an echo to a position once  held by previous Democratic Pres Bill Clinton's wife in 1993, will be  run by Nancy-Ann De-Parle, who then assisted Hillary Clinton (the new  Secretary of State), the then architect of health care reform.

A summit at the White House to discuss the President's goals for change  is due to be held in the first week of March, gathering 120 politicians,  lobbyists and activists. During the election campaign which ended last  November, Pres Obama's agenda appeared to focus on a  government-subsidized health insurance plan that would compete against  private providers in a government-controlled market place. Critics claim  that such a scheme will fail to offer Americans any choice, because  private operators will be "crowded out."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Companies featured in this story

More ones to watch >




Today's issue

Company Spotlight